On June 11, 2026, Lunai Bioworks, Inc. (the "Company") received a letter from The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Panel has determined that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share (the "Bid Price Rule"), and that the Company has met the terms set forth in the Nasdaq Hearings Panel's decision and extension letters dated April 20, 2026, and May 12, 2026, respectively.